Tickerspy’s Stem Cell Stock Index (*RSXTM) took off today, rising nearly 13%. The movement followed a release from the National Institutes of Health (NIH) announcing that 13 embryonic stem cell lines were approved for funding.
Opexa Therapeutics Inc (NASDAQ: OPXA) led the rise in stem cell stocks, surging over 40%. The company seeks to develop treatments to major illnesses, such as multiple sclerosis and diabetes, through stem cell research. The company’s stock has risen 2837% off its lows for the year.
StemCells Inc (NASDAQ: STEM) rose over 30% to a high of $1.45. The company engages in research aimed at developing treatment for organ damage using stem cells. The company’s stock is up over 1544% off its low for the year.
Garrett W. McIntyre